Lung Therapeutics Overview
- Year Founded
-
2013
- Status
-
Acquired/Merged
- Employees
-
13
- Latest Deal Type
-
M&A
Lung Therapeutics General Information
Description
Developer of novel peptide drugs intended to facilitate treatments for fibrosis and lung conditions. The company's drugs trigger both survival signals for alveolar epithelial cells and destruction signals for unwanted fibrotic cells, enabling medical practitioners to treat idiopathic pulmonary fibrosis and loculated pleural effusion among other life-threatening lung diseases.
Contact Information
Website
www.lungtx.comCorporate Office
- 3801 South Capital of Texas Highway
- Suite 330
- Austin, TX 78704
- United States
Corporate Office
- 3801 South Capital of Texas Highway
- Suite 330
- Austin, TX 78704
- United States
Lung Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Merger/Acquisition | 31-Oct-2023 | Completed | Clinical Trials - Phase 2 | |||
| 12. Later Stage VC | 04-Apr-2022 | Completed | Clinical Trials - Phase 2 | |||
| 11. Grant | 21-Aug-2020 | Completed | Clinical Trials - Phase 1 | |||
| 10. Debt - PPP | 14-Apr-2020 | Completed | Clinical Trials - Phase 1 | |||
| 9. Later Stage VC (Series C) | 31-Oct-2019 | Completed | Clinical Trials - Phase 1 | |||
| 8. Accelerator/Incubator | 01-Jan-2018 | Completed | Clinical Trials - Phase 1 | |||
| 7. Early Stage VC (Series B) | 01-Mar-2016 | Completed | Clinical Trials - Phase 1 | |||
| 6. Grant | 27-Oct-2015 | Completed | Clinical Trials - Phase 1 | |||
| 5. Early Stage VC (Series A) | 10-Sep-2014 | $2.75M | $2.75M | Completed | Clinical Trials - Phase 1 | |
| 4. Accelerator/Incubator | 12-Mar-2014 | Completed | Clinical Trials - Phase 1 |
Lung Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 10,888,283 | $0.000100 | $0.02 | $0.27 | $0.27 | 1x | $0.27 | 12.06% |
Lung Therapeutics Comparisons
Industry
Financing
Details
Lung Therapeutics Competitors (15)
One of Lung Therapeutics’s 15 competitors is Aqualung Therapeutics, a Venture Capital-Backed company based in Tucson, AZ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aqualung Therapeutics | Venture Capital-Backed | Tucson, AZ | ||||
| Enterprise Therapeutics | Venture Capital-Backed | Brighton, United Kingdom | ||||
| Avalyn Pharma | Formerly VC-backed | Boston, MA | ||||
| Verona Pharma | Corporate Backed or Acquired | London, United Kingdom | ||||
| Corbus Pharmaceuticals Holdings | Formerly VC-backed | Norwood, MA |
Lung Therapeutics Patents
Lung Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024015857-A2 | Modified caveolin-1 peptide formulations and methods of manufacturing and use thereof | Inactive | 12-Jul-2022 | ||
| WO-2024015857-A3 | Modified caveolin-1 peptide formulations and methods of manufacturing and use thereof | Inactive | 12-Jul-2022 | ||
| WO-2023070069-A1 | Modified caveolin-1 peptides for the treatment of chronic kidney disease | Inactive | 22-Oct-2021 | ||
| WO-2023283639-A1 | Epithelial sodium channel (enac) inhibitor conjugates and methods for use thereof | Inactive | 08-Jul-2021 | ||
| WO-2022266410-A1 | Modified caveolin-1 peptides for the treatment of post-acute covid-19 | Inactive | 17-Jun-2021 | A61K38/177 |
Lung Therapeutics Signals
Lung Therapeutics Former Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ACC Bioscience Incubator | Accelerator/Incubator | |||
| Austin Technology Incubator | Accelerator/Incubator | Minority | ||
| Bios Partners | Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| DEFTA Partners | Venture Capital | Minority |
Lung Therapeutics FAQs
-
When was Lung Therapeutics founded?
Lung Therapeutics was founded in 2013.
-
Where is Lung Therapeutics headquartered?
Lung Therapeutics is headquartered in Austin, TX.
-
What is the size of Lung Therapeutics?
Lung Therapeutics has 13 total employees.
-
What industry is Lung Therapeutics in?
Lung Therapeutics’s primary industry is Drug Discovery.
-
Is Lung Therapeutics a private or public company?
Lung Therapeutics is a Private company.
-
What is Lung Therapeutics’s current revenue?
The current revenue for Lung Therapeutics is .
-
How much funding has Lung Therapeutics raised over time?
Lung Therapeutics has raised $65.8M.
-
Who are Lung Therapeutics’s investors?
ACC Bioscience Incubator, Austin Technology Incubator, Bios Partners, , and DEFTA Partners are 5 of 16 investors who have invested in Lung Therapeutics.
-
Who are Lung Therapeutics’s competitors?
Aqualung Therapeutics, Enterprise Therapeutics, Avalyn Pharma, Verona Pharma, and Corbus Pharmaceuticals Holdings are some of the 15 competitors of Lung Therapeutics.
-
When was Lung Therapeutics acquired?
Lung Therapeutics was acquired on 31-Oct-2023.
-
Who acquired Lung Therapeutics?
Lung Therapeutics was acquired by Rein Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process